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Abstract
Background: Antidepressants promote neuronal structural plasticity in young-adult rodents, but little is known of
their effects on older animals. The polysialylated form of the neural cell adhesion molecule (PSA-NCAM) may
mediate these structural changes through its anti-adhesive properties. PSA-NCAM is expressed in immature
neurons and in a subpopulation of mature interneurons and its expression is modulated by antidepressants in the
telencephalon of young-adult rodents.
Results: We have analyzed the effects of 14 days of fluoxetine treatment on the density of puncta expressing PSA-
NCAM and different presynaptic markers in the medial prefrontal cortex, hippocampus and amygdala of middle-
aged (8 months old) rats. The density of puncta expressing PSA-NCAM increased in the dorsal cingulate cortex, as
well as in different hippocampal and amygdaloid regions. In these later regions there were also increases in the
density of puncta expressing glutamic acid decarboxylase 65/67 (GAD6), synaptophysin (SYN), PSA-NCAM/SYN and
PSA-NCAM/GAD6, but a decrease of those expressing vesicular glutamate transporter 1 (VGluT1). Since there is
controversy on the effects of antidepressants on neurogenesis during aging, we analyzed the number of
proliferating cells expressing Ki67 and that of immature neurons expressing doublecortin or PSA-NCAM. No
significant changes were found in the subgranular zone, but the number of proliferating cells decreased in the
subventricular zone.
Conclusions: These results indicate that the effects of fluoxetine in middle-aged rats are different to those
previously described in young-adult animals, being more restricted in the mPFC and even following an opposite
direction in the amygdala or the subventricular zone.
Background
Recent hypotheses support the idea that abnormalities
in neuronal structural plasticity may underlie the etio-
pathogenesis of major depression [1,2]. Accordingly, it
has been shown that patients and animal models of this
disorder show changes in the volume of certain cerebral
regions, such as the hippocampus, the medial prefrontal
cortex or the amygdala, which are related to the reorga-
nization of neuronal structure and may affect their con-
nectivity [3,4]. However, these structural changes are
not limited to neuronal remodeling, they may also affect
the production of new neurons, specially in the adult
hippocampus [5-8]. Interestingly, antidepressant treat-
ment is able to revert or block this plasticity in experi-
mental animals and humans [9-13]. In fact, different
lines of evidence indicate that both neuronal remodeling
[14-17] and adult neurogenesis [12,18] may play an
important role in the way of action of antidepressant
drugs.
The regulation of the expression of cell adhesion
molecules is critical for the neuronal structural remodel-
ing induced by aversive experiences or by antidepressant
treatments [19]. Previous results from our laboratory
have shown that chronic treatment with the serotonin
(5HT) reuptake inhibitor fluoxetine, a commonly used
antidepressant, influences the expression of the
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(PSA-NCAM) in different regions of the CNS of young-
adult animals [20,21]. Similar results have been obtained
with another antidepressant, imipramine [17]. PSA-
NCAM, due to its anti-adhesive properties, creates a
steric impediment for cell adhesion and, consequently,
promotes structural plasticity [22]. In fact, the changes
in PSA-NCAM expression induced by chronic fluoxetine
treatment are accompanied by parallel changes in the
expression of the synaptic protein synaptophysin (SYN),
suggesting the occurrence of synaptic remodeling [21].
PSA-NCAM expression is abundant during development
and, although it decreases markedly during adulthood, it
is still detectable in many cerebral regions, such as the
medial prefrontal cortex (mPFC) [23,24], amygdala [25]
and hippocampus [26], which are known to be involved
in major depression. In these regions, PSA-NCAM is
expressed in immature neu-rons, such as those in the
hippocampal subgranular zone (SGZ) [27] and the sub-
ventricular zone (SVZ) [28], but it is also expressed in a
subpopulation of mature interneurons [29,24], which
have reduced syn-aptic input and morphological features
compared with other interneurons lacking PSA-NCAM
[30]. Pre-vious work in our laboratory demonstrated
that 5HT, acting via 5HT3 receptors is able to regulate
PSA-NCAM expression in the mPFC of adult rats [20].
The effects of antidepressants on neuronal plasticity
are not restricted to structural remodeling of neurons
and their connections, they may also influence the gen-
eration and incorporation of new neurons in the adult
CNS. Chronic antidepressant treatments increase neuro-
genesis in the SGZ of the dentate gyrus and the SVZ of
young-adult rodents [31,32], and this increase appears
to be required at least for part of the behavioral
improvement observed in the treated animals [18].
However, other studies are in disagreement with these
findings and have found that antidepressants do not
produce an increase in neurogenesis in the SGZ [33,34].
Despite all these interesting findings regarding the
effects of antidepressants on neuronal plasticity, it has
to be noted that most of the experiments have been per-
formed using young-adult rodents, usually 2-3 months
old. Consequently, there is controversy on whether anti-
depressants, and specifically 5HT reuptake inhibitors,
exhibit the same efficacy within different age groups.
This is particularly interesting because aging influences
both neurogenesis [35] and PSA-NCAM expression
[36]. Studies on the effects of antidepressant treatment
using older animals are still scarce: Only a few works
have studied neurogenesis in the SGZ [32,37], but not
in the SVZ and, to our knowledge, none has studied
other types of neuronal structural plasticity.
We have analyzed the effects of 14 days of chronic
fluoxetine treatment on middle-aged (8 month old) rat
brains, studying the expression of PSA-NCAM and that
of different presynaptic proteins in regions known to be
specially affected in patients and in animal models of
major depression, as well as by antidepressant treatment,
such as the mPFC, the amygdala, and the hippocampus
[ 3 8 - 4 2 ] .W eh a v es t u d i e dt h ee x p r e s s i o no fS Y Nag e n -
eral synaptic marker, glutamic acid decarboxylase 65/67
(GAD6), a marker for inhibitory synapses and the vesi-
cular glutamate transporter 1 (VGluT1), a marker of
excitatory synapses. To study the effects of fluoxetine on
adult neurogenesis, we have analyzed the numbers of
im-mature cells, using immunohistochemistry for dou-
blecortin (DCX) and PSA-NCAM, and those of prolife-
rating cells with Ki67 in the two neurogenic niches of
the adult brain: the SGZ and the SVZ.
Methods
Animal treatments
Fourteen adult male Wistar rats (8 months old) were
used in this experiment. All the rats were maintained in
standard conditions of light (12 hour cycles) and tem-
perature, with no limit in the access to food or water.
All animal experimentation was conducted in accor-
dance with the Directive 2010/63/EU of the European
Parliament and of the Council of 22 September 2010 on
the protection of animals used for scientific purposes
and was approved by the Committee on Bioethics of the
Universitat de València. Every effort was made to mini-
mize the number of animals used and their suffering.
Rats were chronically injected intraperitoneally either
with the antidepressant fluoxetine (n = 7, 10 mg/kg), or
with saline solution (n = 7), during 14 days (once daily
at 10.00 am). Previous studies have shown that this dose
produces behavioral changes and increases in the
expression of plasticity-related molecules [21,58]. The
day after these treatments, rats were perfused transcar-
dially under deep chloral hydrate anesthesia (chloral
hydrate 4%, 1 ml/100 gr), first with saline and then with
4% paraformaldehyde in so-dium phosphate buffer (PB
0.1 M, pH 7.4). After perfusion, the brains were
extracted and cryoprotected with 30% sucrose in PB.
Brains were cut into 50 μm thick sections with a freez-
ing sliding microtome, collected in 10 subseries and
stored at - 20°C in 30% glycerol, 30% ethylene glycol in
PB 0.1 M until used.
Immunohistochemistry
Tissue was processed free-floating as follows: Briefly,
sections were incubated for 1 min in an antigen
unmasking solution (0.01 M citrate buffer, pH 6) at 100°
C. After cooling down the sections to room tempera-
ture, the endogenous peroxidase was blocked with 10
m i ni n c u b a t i o ni nas o l u t i o no f3 %H 2O2 in phosphate
buffered saline (PBS). Afterwards, slices were incubated
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Triton-X100 (Sigma) in PBS with for 1 hour; then, they
were incubated overnight at room temperature with
goat polyclonal anti-doublecortin (DCX) (C-18; 1:250;
Santa Cruz Biotechnology, Inc.), mouse monoclonal
anti-PSA-NCAM IgM (1:1400; Abcys SA) or mouse
monoclonal anti-Ki67 IgG (1:2000; Novocastra). After
washing, sections were incubated for 30 min with bioti-
nylated donkey anti-goat IgG, donkey anti-mouse IgM
or donkey anti-mouse IgG (1:200; Jackson Immunore-
search) antibodies, followed by an avidin-biotin-peroxi-
dase complex (ABC, Vector Laboratories) for 30 min in
PBS. Color development was achieved by incubating
with 0,5% 3,3’ diaminobenzidine tetrahydrochloride
(DAB, Sigma) and H2O2 for 4 min. All the sections
passed through all procedures simultaneously to mini-
mize any difference from immunohistochemical staining
itself.
For double fluorescence immunohistochemistry, slices
were incubated overnight with rabbit polyclonal anti-
synaptophysin (SYN) IgG (1:1000; Chemicon Int. Inc.)
and mouse monoclonal anti-PSA-NCAM IgM (1:1400;
Abcys SA). Then, were incubated for 1 hour with don-
key anti-rabbit IgG Dylight 488 and donkey anti-mouse
IgM Dylight 555 (1:200; Jackson Immunoresearch).
For triple immunohistochemistry, the procedure was
similar but using a combination of anti-PSA-NCAM,
anti-glutamic acid decarboxylase 65/67 (GAD6; 1:500;
Developmental Studies Hybridoma Bank) and anti-vesi-
cular glutamate transporter (VGluT1; 1:2000; Chemicon
Int. Inc.) antibodies. In this case the following secondary
antibodies were used: anti-mouse IgM Dylight 555, anti-
mouse IgG subtype 1 specific Dylight 488 and anti-gui-
nea pig IgG Dylight 647 respectively.
Quantitative analysis
All the slides containing sections destined to quantita-
tive analysis were coded and their code was not broken
until the analyses were finished.
The volume of the mPFC, the hippocampus and the
lateral and basolateral region of the amygdala was esti-
mated using Volumest, an ImageJ plugin for volume
estimation using an stereological method. For this analy-
sis we used the tissue processed with PSA-NCAM
immunohistochemistry and developed with DAB was
used.
The images used for the analysis of neuropil puncta
were obtained with a confocal microscope (Leica TCS
SPE) and parallel subseries of Nissl stained sections
were used as guides to help locate the regions of inter-
est. We analyzed layer V of two different regions of the
medial prefrontal cortex (mPFC): the prelimbic cortex
(PrL) in a single section corresponding to Bregma +2.20
mm and another one of the dorsal cingulate cortex
(Cg2) (Bregma +1 mm). In the amygdala, five nuclei
were analyzed in one section (Bregma -3.30 mm):
basomedial, lateral, medial, central and basolateral. Dif-
ferent regions and strata of the hippocampus were also
analyzed in another section (Bregma -4.30 mm): the
molecular layer of the dentate gyrus, the strata lacuno-
sum-moleculare, radiatum and oriens of CA1 and the
stratum lucidum of CA3. Confocal z-stacks covering the
whole depth of the sections were taken with 1 μms t e p
size and only subsets of confocal planes with the opti-
mal penetration level for each antibody were selected.
On these planes, small regions of the neuropil (505
μm
2) were selected for analysis, in order to avoid blood
vessels and cell somata.
Images were processed using ImageJ software as fol-
lows: the background was substracted with rolling value
of 50, converted to 8-bit deep images and binarized
using a determined threshold value. This value
depended on the marker and the area analyzed and was
kept the same for all images with the same marker and
area. Then, the images were processed with a blur filter
to reduce noise and separate closely apposed puncta.
Finally, the number of the resulting dots per region was
counted, as well as the colocalization between PSA-
NCAM and the different pre-synaptic markers (Addi-
tional File 1, Figure S1). In addition, we also analyzed
the size of the dots and the total surface covered by
the puncta after binarization. Means were determined
for each animal group and the data were subjected to
two-way ANOVAs with repeated measures followed by
Bonferroni post hoc test.
The density of DCX, PSA-NCAM and Ki67 expressing
cells in the SGZ of the dentate gyrus was estimated as
described before [25]. Briefly, sections were selected by
a 1:10 fractionator sampling covering the whole rostral
to caudal extension of the dentate gyrus and on each
section all labeled cells within the region of interest
were counted. Cell somata were identified and counted
with a 40 × objective using an Olympus CX41 micro-
scope. The volume of the different areas analyzed was
determined for each animal using the Cavalieri’s
method. Student’s t-test was performed for statistical
analysis.
In the SVZ, a single section between Bregma +0.48
and +0.7 mm, was analyzed for DCX, PSA-NCAM and
Ki67 immunohistochemistry. The number of immunor-
eactive cells was estimated following a modification of
the method described by Hansson et al.[ 4 3 ] .K i 6 7
expressing nuclei were counted using automatic count-
ing software as described above for immunoreactive
puncta, analyzing an area of 100 μm
2 and then
expressed as the number of immunoreactive positive
cells per mm
2.D e n s i t i e so fD C Xa n dP S A - N C A M
expressing cells were too high for a correct individual
Guirado et al. BMC Neuroscience 2012, 13:5
http://www.biomedcentral.com/1471-2202/13/5
Page 3 of 13cell count. Therefore, we performed densitometry of
small areas within the SVZ, using a 40 × magnification,
as described before [20].
Results
Weight of the animals and volume of the different
structures analyzed
In concordance with previous studies [44,45], chronic
fluoxetine treatment produced a significant diminution
of weight gain (p < 0.001) after 14 days, when compar-
ing the relation final weight/initial weight between the
treated animals (0.877 ± 0.017) and the controls (1.017
± 0.009) (Figure 1).
We also analyzed the effects of chronic fluoxetine
treatment on the volume of the different cerebral
structures studied. We did not observe changes in
the volume of the mPFC or the amygdala, but we
found an increase in the volume of the hippocampus
of the animals treated with fluoxetine (p = 0.001,
Figure 1).
Expression of plasticity-related Molecules
Medial prefrontal cortex
The expression pattern of PSA-NCAM in the mPFC was
similar to that described previously [23]: All regions
within the mPFC showed a moderate intensity of stain-
ing in layer I, nearly lack of staining in layer II, weak
staining in layer III and intense staining in layers V-VI
(Figure 2).
In this cortical region, there was an increase in the
density of PSA-NCAM expressing puncta in the fluoxe-
tine treated animals in the dorsal cingulate cortex (Cg2)
(p = 0.043), but not in the prelimbic cortex (PrL) (Fig-
ure 3 and Additional File 2, Table S1). No differences
were found in the density of puncta expressing synapto-
physin (SYN), glutamic acid decarboxylase 65/67
(GAD6), or vesicular glutamate transporter 1 (VGluT1)
in any of the regions studied (Figure 3 and Additional
File 2, Table S1)). We did not find changes in the den-
sity of puncta colocalizing PSA-NCAM/SYN, PSA-
NCAM/GAD6 or PSA-NCAM/VGluT1 neither in the
PrL nor in the Cg2 (Figure 2 and Additional File 2,
Table S1).
We did not find changes neither in the dot size nor in
the surface covered by puncta in any of the regions and
the markers analyzed (Additional File 3, Figure S2).
Amygdala
As described previously [24], low levels of PSA-NCAM
expression were found in the neuropil of the lateral and
basolateral amygdaloid nuclei. By contrast, PSA-NCAM
expression was denser and more intense in the central,
medial and basomedial nuclei (Figure 2).
In the fluoxetine treated group we found significant
increases in the density of PSA-NCAM expressing
puncta in the central amygdaloid nucleus (p = 0.001), of
SYN expressing puncta in the lateral (p = 0.049) and
basolateral amygdaloid nuclei (p = 0.047) and of GAD6
expressing puncta in the basolateral nucleus (p = 0.005)
(Figure 4 and Additional File 2, Table S1). On the con-
trary, we found a significant decrease in the number of
VGluT1 expressing puncta in the basolateral amygdaloid
nucleus (p = 0.04) (Figure 4 and Additional File 2, Table
S1). We also found an increase in PSA-NCAM/SYN (p
= 0.007) and PSA-NCAM/GAD6 (p = 0.041) expressing
puncta in the central amygdala. No changes in the den-
sity of these double-labeled puncta were observed in any
of the other amygdaloid nuclei studied (Figure 4 and
Additional File 2, Table S1).
We also found changes similar to those described for
puncta density when analyzing the dot size and the sur-
face covered by these puncta. In the central amygdaloid
nucleus we observed an increase both in the dot size
and the surface covered by PSA-NCAM expressing
puncta (p = 0.027 and 0.011). In the lateral nucleus we
only observed an increase in the dot size of puncta
expressing SYN (p = 0.038). By contrast, in the basolat-
eral nucleus we found an increase in the dot size and
surface covered by puncta expressing GAD6 (p = 0.011
and 0.018) and a decrease in both, the dot size and the
surface covered by puncta expressing VGluT1 (p =
0.005 and 0.007) (Additional File 4, Figure S3).
Hippocampus
PSA-NCAM expression in the hippocampus was similar
to that described previously [26]: briefly, the most
intense expression of PSA-NCAM was located in the
somata and apical dendrites of granule cells in the SGZ
of the dentate gyrus, as well as in the neuropil of the
hilus and the mossy fibers. A weaker and more diffuse
expression of PSA-NCAM could be found in the neuro-
pil of other regions of the hippocampus, such as the
molecular layer of the dentate gyrus and the strata lacu-
nosum-moleculare, radiatum and oriens of CA1 and
CA3 (Figure 2), where PSA-NCAM expressing cell
somata could also be found [29].
Figure 1 Graphs showing (A) the body weight change through
the experiment for the control and fluoxetine group and (B)
the effect of the chronic fluoxetine treatment on the volume
of the different structures studied. Statistically significant (* P <
0.05, ** P < 0.01, *** P < 0.001) Student t-test.
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cant increases in the density of PSA-NCAM expressing
puncta in the molecular layer (p = 0.045), stratum luci-
dum (p = 0.032) and stratum lacunosum-moleculare (p
< 0.001) (Figure 5 and Additional File 2, Table S1).
Similar increases were found in the density of SYN
expressing puncta in the strata lucidum (p = 0.012) and
lacunosum-moleculare (p = 0.038). We also found a
significant increase (p = 0.018) in the density of GAD6
expressing puncta in the stratum lacunosum-moleculare.
By contrast, we found a decrease in the density of
VGluT1 expressing puncta in the strata lacunosum-
moleculare (p = 0.021) and radiatum (p = 0.030) of CA1
(Figure 5 and Additional File 2, Table S1). When study-
ing the density of puncta co-expressing PSA-NCAM
and each of the other markers, we observed an increase
Figure 2 Confocal images showing the expression of PSA-NCAM, VGluT1 and GAD6 in the different regions of the hippocampus (B, E
and H), the amygdala (B, D and G) and the mPFC (A, C and F). Scale bar = 200 μm in A and B, 100 μm in C, D and E and 1 μm in F, G and
H.
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(p = 0.008) in the stratum lacunosum-moleculare, but
no change was observed in those co-expressing PSA-
NCAM/GAD or PSA-NCAM/VGluT1 (Figure 5 and
Additional File 2, Table S1).
Finally, when analyzing the dot size and the surface
covered by immunoreactive puncta, we also observed
changes in most of the regions that showed differences
in the density of puncta in these structures. In the stra-
tum lacunosum-moleculare we observed an increase in
the dot size and the surface covered by puncta expres-
sing PSA-NCAM (p = 0.011 and < 0.001) and GAD6 (p
= 0.047 and 0.021), while there was only an increase in
dot size in those expressing SYN (p = 0.044) and a
decrease in both dot size and surface covered by those
expressing VGluT1 (p = 0.035 and 0.017). We also find
a decrease in both the dot size and the surface covered
by puncta expressing VGluT1 in the stratum radiatum
(p = 0.015 and 0.007) (Additional File 5, Figure S4).
Adult neurogenesis
No change in the density of cells expressing DCX or
PSA-NCAM was observed in the subgranular zone
(SGZ) of the dentate gyrus after chronic fluoxetine
treatment (Figure 6). However, when analyzing the
number of Ki67 expressing nuclei there was a trend
Figure 3 Graphs representing the expression of puncta for the different markers and its colocalization in the prelimbic and cingulate
cortex of the medial prefrontal cortex. White bars represent control animals and black bars represent fluoxetine treated animals respectively.
A and B are focal planes showing the expression of PSA-NCAM in (1) the prelimbic and (2) the cingulate cortex. Scale bar: 200 μm.
Figure 4 Graphs representing the expression of puncta for the different markers and its colocalization in different areas of the
amygdala. White bars represent control animals and black bars represent fluoxetine treated animals respectively. A is a focal plane showing the
expression of PSA-NCAM in the (1) basomedial (2) lateral, (3) medial, (4) basolateral and (5) central nuclei of the amygdala. Scale bar: 200 μm.
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u r e6 ) .I nt h es u b v e n t r i c u l a rz o n e( S V Z )w ea l s of a i l e d
to find changes in the expression of DCX or PSA-
NCAM, but we observed a dramatic significant decrease
in the number of Ki67 immunoreactive nuclei in the
treated group (p < 0.001) (Figure 6).
Discussion
Our results indicate that in middle-aged rats chronic
fluoxetine treatment induces changes in the expression
of molecules related to neuronal structural plasticity.
These changes occur in the same direction of those
observed previously in young-adult animals in the hip-
pocampus and the mPFC, although to a reduced extent
in this later region. However, they follow the opposite
direction in the amygdala. We have also observed that,
in contrast with what has been observed in young-adult
rats, there is a negative impact of fluoxetine on cell pro-
liferation in the SVZ and apparently a lack of effect in
the SGZ.
PSA-NCAM expression as an indicator of neuronal
structural plasticity
Previous experiments have demonstrated that PSA-
NCAM expression is sensible to fluoxetine treatment,
acting through 5HT3 receptors [20]. However, since
other 5HT receptors are known to mediate the effects
of fluoxetine, they may also influence PSA-NCAM
expression [46-51]. Many PSA-NCAM expressing struc-
tures in the cerebral cortex [24,29,30] and the amygdala
[52] of rodents belong to mature interneurons. Conse-
quently, changes in PSA-NCAM expression should pri-
marily affect the structure of these inhibitory. In this
line, we have recently reported that PSA-NCAM expres-
sing cortical interneurons have reduced synaptic input
and decreased dendritic arborization and spine density
when compared with neighboring interneurons lacking
PSA-NCAM [30]. In fact, a previous report from our
laboratory using a dopamine D2 receptor antagonist,
which increases PSA-NCAM expression in the mPFC,
also resulted in a parallel upregulation of GAD67
expression [53]. It is possible then, that the changes in
PSA-NCAM expression observed in the present study
affect the connectivity of certain interneurons, regulating
the surface of preexisting plasma membrane available
for the establishment of synaptic contacts. Another non-
excluding possibility may be that, given its anti-adhesive
properties, changes in PSA-NCAM expression may reg-
ulate the ability of certain interneurons to remodel the
structure of their neurites, and consequently their con-
nections, in response to fluoxetine treatment.
Comparison of the effects of chronic fluoxetine treatment
on the expression of PSA-NCAM and presynaptic markers
between middle-aged and young-adult animals
The present results in the mPFC, showing only an
increase in the density of PSA-NCAM expressing puncta
in the dorsal cingulate cortex, are more restricted than
those found previously in young-adult rats, which
showed increases in every region and layer of the mPFC
[20]. The lack of changes in the density of puncta
expressing presynaptic markers is also in contrast with
previous reports using young-adult rats, which showed
increases in SYN expression in deep layers of the pre-
limbic and infralimbic cortices [21] and of VGluT-1
mRNA expression in the cingulate cortex [54].
Figure 5 Graphs representing the expression of puncta for the different markers and its colocalization in different areas of the
hippocampus. White bars represent control animals and black bars represent fluoxetine treated animals respectively. A is a focal plane showing
the expression of PSA-NCAM in the strata (1) Lucidum, (2) Molecular, (3) Lacunosum Moleculare, (4) Radiatum and (5) Oriens of the
hippocampus. Scale bar: 200 μm.
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adult rats found a similar increase in PSA-NCAM
expression in the stratum lucidum, but not in the rest
of hippocampal strata studied [21]. Since in young-adult
rats antidepressants promote an increase in the density
of PSA-NCAM expressing cells in the SGZ [17], fluoxe-
tine may be affecting PSA- N C A Me x p r e s s i o ni nt h e
stratum lucidum by increasing the production or
Figure 6 Graphs representing (A) the total number of cells expressing immature and proliferative markers in the subgranular zone
(SGZ) of the hippocampus and (B) the gray level of doublecortin (DCX) and PSA-NCAM and the density of Ki67 in the subventricular
zone (SVZ). White bars represent control animals and black bars represent fluoxetine treated animals respectively. (C) Micrographs showing the
expression of Ki67 in the SVZ and (D) DCX in the SGZ. Scale bar: 100 μm (C and D) and 50 μm (insets in D).
Guirado et al. BMC Neuroscience 2012, 13:5
http://www.biomedcentral.com/1471-2202/13/5
Page 8 of 13accelerating the maturation of immature granule cells,
some of which may have already sent PSA-NCAM
expressing mossy fibers to this layer [55]. However, our
results clearly indicate that the number of these cells is
not affected by fluoxetine in middle-aged rats, suggest-
ing that changes in PSA-NCAM expressing puncta are
not linked to adult neurogenesis. In connection to this,
a recent report has shown that chronic fluoxetine treat-
ment may produce a dematuration of granule cells [56].
S i n c em a n ym o s s yf i b e r si nt h es t r a t u ml u c i d u ma r e
polysialylated by St8SiaII, the enzyme responsible for
the polysialylation of immature neurons in the adult cer-
ebral cortex [57], this putative dematuration induced by
fluoxetine may explain the increase in PSA-NCAM
expression that we observe in this stratum. In conso-
nance with this hypothesis and with previous studies in
young-adult rats [21,58], we have failed to find any sig-
nificant difference in the density of SYN expressing
puncta in the stratum lucidum, which may indicate that
the changes in PSA-NCAM are not related to the gen-
esis of new functional synaptic contacts. By contrast, the
increase of PSA-NCAM expressing puncta in the stra-
tum lacunosum-moleculare of middle-aged rats is
accompanied by an increase in the density of SYN
expressing puncta and of puncta co-expressing PSA-
NCAM/SYN, suggesting that these structures corre-
spond to synapses. Interestingly, in the stratum lacuno-
sum-moleculare of middle-aged animals we also found
an increase in the density of GAD6 expressing puncta,
and a decrease in the density of those expressing
VGluT1, which may indicate that the upregulation of
PSA-NCAM expression may be linked to changes in
inhibitory circuits, probably involving the formation of
inhibitory synapses.
Chronic fluoxetine treatment in young-adult rats
decreases PSA-NCAM and SYN expression in most
amygdaloid nuclei [21] and decreases the number of
PSA-NCAM expressing neurons in this limbic region
[59]. By contrast, in middle-aged rats we not only have
failed to observe decreases in the density of puncta
expressing PSA-NCAM or SYN, but have observed sig-
nificant increases in the density of PSA-NCAM expres-
sing puncta in the central nucleus and of those
expressing SYN in the lateral and basolateral nuclei.
There is, in fact, a general tendency for an increase in
the density of puncta expressing PSA-NCAM, SYN and
GAD6 in all the amygdaloid nuclei studied. Moreover,
despite the fact that no significant changes in puncta
expressing exclusively GAD6 or SYN were observed in
the central amygdala, the density of puncta coexpressing
PSA-NCAM and each of these two markers also
increases significantly, suggesting that changes in PSA-
NCAM expression may be associated to the generation
or remodeling of inhibitory synapses in this region. In
the basolateral amygdala, chronic fluoxetine treatment
may also influence positively synaptic plasticity of inhi-
bitory circuits, as indicated by increased densities of
GAD6 and SYN expressing puncta, while the density of
those expressing VGluT1 is decreased.
It is possible that substantial differences in 5HT con-
tent and in the expression of its receptors, transporters,
etc... exist in middle-aged animals. The levels of 5HT
are generally reduced in the brain of aged rats [60] and,
although there are no studies in middle-aged animals, it
is possible that they are already reduced at this age.
There is also evidence indicating that the expression
5HT1A receptor, which has an important role in the
antidepressant effects of 5HT reuptake inhibitors
[61,62], is lower in young-adult than in adolescent rats
[59]. Additionally, other factors such as changes in inhi-
bitory neurotransmission may also influence the effects
of fluoxetine in middle-aged animals, particularly in the
amygdala, where decreases in GABA concentration and
hyperactivity have been described during aging [63,64].
Effects of fluoxetine treatment on neurogenesis
The present results on adult hippocampal neurogenesis
are in agreement with previous studies showing that
neither proliferation nor neuronal survival/differentia-
tion is affected by chronic antidepressant treatment in
middle-aged rodents [32,37]. This lack of response of
the SGZ in middle-aged animals must be due to changes
that alter the molecular pathways by which 5HT stimu-
lates neurogenesis. There is an age-dependent reduction
in the levels of 5HT [60] and some of its receptors [65]
in the hippocampus. Since glucocorticoids are important
modulators of adult hippocampal neurogenesis and
these steroids are particularly elevated during aging [66],
they may also influence the neurogenic response to anti-
depressants in middle-aged animals. In fact, glucocorti-
coids decrease 5HT transporter expression [67] and the
neurogenic action of fluoxetine is blocked by a flattened
corticosterone rhythm induced by artificially enhanced
glucocorticoid levels [68]. Additionally, a previous study
has clearly shown that intraperitoneal injections per se
have effects on the structure of neurons, at least in the
mPFC [69]. This effects are similar to those observed
after chronic stress [41]and it is very likely that this pro-
cedure also affects some of the plasticity parameters
measured in our study, including neurogenesis, which is
importantly influenced by chronic stress [8].
Other molecules known to modulate adult neurogen-
esis, including neurotransmitters, such as glutamate act-
ing on NMDA receptors [70] and GABA [71], or
trophic factors, such as BDNF [72], can be influenced by
antidepressants, including fluoxetine [73-76]. Conse-
quently, age-dependent changes in their expression or in
the molecular pathways in which these molecules are
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effects of antidepressants.
In contrast with previous studies using fluoxetine [31]
and 5HT receptor agonists [77] in young-adult rodents,
which found increases in the number of proliferating
cells in the SVZ, we have found the opposite effect. On
the other hand, our results are in agreement with a
recent report describing that in young-adult mice 3
weeks of fluoxetine treatment do not affect cell prolif-
eration in the SVZ, but that the extension of this treat-
ment to 6 weeks produces a significant deficit in the
number of dividing cells in this region [78]. These
results indicate that the SVZ of middle-aged rodents is
more sensible to fluoxetine treatment, since a significant
decrease in cell proliferation can be achieved with a
shorter treatment. It is possible that the lack of differ-
ences in the number of neuroblasts in the SVZ may be
d u et oah o m e o s t a t i cp a r a l l e lc h a n g ei nt h en u m b e ro f
apoptotic cells in this region, as suggested previously
[79]. Alternatively, fluoxetine could impair neuronal
migration, which may cause accumulation of neuroblasts
in the SVZ.
Implication of the present results on antidepressant
therapy
In light of the neuroplastic hypothesis of depression [1],
our results indicate that antidepressant treatment in
middle-aged individuals also has an important impact
on neuronal structure and connectivity. Consequently, it
may have relevant consequences on the therapeutics of
major depression. In the present results, we have shown
that chronic fluoxetine treatment increases the volume
of the hippocampus and the expression of molecules
related to structural plasticity and inhibitory neurotrans-
mission. These phenomena may counteract the
decreases in hippocampal volume and balance the
increases in excitatory neurotransmission observed in
depressed patients and in animal models of this disorder
[8]. Similar, although lighter, effects have been observed
in the amygdala. In this region, the increases in the
expression of molecules related to structural plasticity
and inhibitory neurotransmission may compensate the
structural changes observed in inhibitory and excitatory
neurons, which accompany the increased excitation
observed in this limbic region in animal models of
depression [80]. The effects of fluoxetine in the mPFC
of middle-aged rats are more discrete, but it is reason-
able to think that the increase in PSA-NCAM expres-
sion may facilitate compensatory structural changes to
overcome the structural atrophy of pyramidal neurons
observed in animal models of depression [42].
By contrast, our results on the effects of fluoxetine on
adult neurogenesis do not seem to give support to the
idea that this type of plasticity is important for the
treatment of depression, at least in middle-aged rodents.
It has to be noted, however, that our experiment has
been performed in control animals and that the effects
of fluoxetine on molecules related to neuronal structural
plasticity or in neurogenesis may be more intense or fol-
low a different direction when applied to animal models
of this psychiatric disorder.
Conclusions
Our results indicating substantial differences in the plas-
t i cr e s p o n s eo ft h eC N St of l u o x e t i n ei nm i d d l e - a g e d
animals may be relevant when considering what are the
cellular bases of the behavioral changes associated to
antidepressant action.
As it happens with rodents, middle-aged humans may
also show reduced plasticity in response to antidepres-
sant and, what is more important, this plasticity may fol-
low a different direction in certain brain regions, such as
the SVZ or the amygdala. These results indicate that the
response to antidepressant treatment is more complex
than previously thought and that the age of the subjects
receiving these drugs is an important factor to consider
and a subject for more intensive research.
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